Elevated baseline circulating levels of ANGPT-2 independently predicted an increased risk of major adverse cardiovascular events (HR 2.400) in patients with acute myocardial infarction.
Cohort (n=180)
Double-blind
No
Do baseline circulating ANGPT-2 and TIE-2 levels predict major adverse cardiovascular events in patients with acute myocardial infarction?
Elevated baseline circulating levels of ANGPT-2 and TIE-2 are independent predictors of major adverse cardiovascular events in patients with acute myocardial infarction, offering potential value for risk stratification.
Hazard Ratio: 2.4 (95% CI 1.38–4.523)
p-value: p=0.002
Acute myocardial infarction (AMI) is an acute heart disease that can result in high rates of disability and mortality. Biomarkers can reflect the pathophysiological progress of AMI, such as myocardial ischemia injury, ventricular remodelling and oxidative stress, and provide advantages in the prognostic evaluation of AMI. Finding novel biomarkers can help improve the risk stratification of AMI. A total of 180 patients who were diagnosed with AMI in the Department of Cardiovascular Medicine of Hunan Provincial People’s Hospital from July 2020 to March 2021 were included in this study. Baseline circulating ANGPT-2 and TIE-2 levels were measured, and patients underwent a regular follow-up to record the occurrence of major adverse cardiovascular events (MACE) after discharge. During the entire follow-up period with an average of 444 (356–586) days, 55 patients developed MACE. Multivariate Cox regression analysis revealed that ANGPT-2 (HR: 2.400; 95% CI: 1.380–4.523; P = 0.002) and TIE-2 (HR: 2.004; 95% CI: 1.127–3.562; P = 0.018) were independent predictors of MACE in patients with AMI. The area under the curve (AUC) of circulating ANGPT-2 for predicting MACE was 0.756 (95% CI: 0.682–0.785; P < 0.001), and the AUC of circulating TIE-2 for predicting MACE was 0.664 (95% CI: 0.572–0.755; P < 0.001).The Kaplan-Meier survival curve revealed that patients with an ANGPT-2 level ≥ 1.896 ng/mL had a greater risk of MACE than those with an ANGPT-2 level < 1.896 ng/mL (HR = 3.189; 95% CI: 1.856–5.481; P < 0.001), and patients with a TIE-2 level ≥ 21.886 ng/mL had a greater risk of MACE than those with a TIE-2 level < 21.886 ng/mL (HR = 2.912; 95% CI: 1.681–5.042; P < 0.001). ANGPT-2 and TIE-2 are significantly correlated with the prognosis of AMI, which suggests that they might be potential biomarkers for predicting prognosis.
Tan et al. (Mon,) conducted a cohort in Acute myocardial infarction (AMI) (n=180). Circulating ANGPT-2 and TIE-2 vs. Lower circulating levels was evaluated on Major adverse cardiovascular events (MACE) (HR 2.400, 95% CI 1.380-4.523, p=0.002). Elevated baseline circulating levels of ANGPT-2 independently predicted an increased risk of major adverse cardiovascular events (HR 2.400) in patients with acute myocardial infarction.